Marker Therapeutics (NASDAQ:MRKR) Receives New Coverage from Analysts at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH started coverage on shares of Marker Therapeutics (NASDAQ:MRKR) in a research report sent to investors on Tuesday morning, Benzinga reports. The firm issued a buy rating and a $11.00 price objective on the stock.

Marker Therapeutics Stock Performance

MRKR opened at $4.05 on Tuesday. The company’s 50-day simple moving average is $4.28 and its two-hundred day simple moving average is $3.97. Marker Therapeutics has a 52-week low of $0.90 and a 52-week high of $9.68.

Hedge Funds Weigh In On Marker Therapeutics

A hedge fund recently raised its stake in Marker Therapeutics stock. International Assets Investment Management LLC raised its stake in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) by 1,000.0% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 11,000 shares of the company’s stock after acquiring an additional 10,000 shares during the period. International Assets Investment Management LLC owned approximately 0.12% of Marker Therapeutics worth $60,000 as of its most recent SEC filing. Institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells.